Adding to the clinical relevance of this signaling pathway, aberrant MEK5/ERK5 activation also contributes to increased tumor cell proliferation and metastasis33, inducing a chemoresistant phenotype in both CSCs and non-CSCs36. This evidence concerns the gene MAPK7 and neoplasm.